2024 targets achieved; markets appreciated shareholder rewards
30/01/25 -"Even though Q4 results were somewhat behind the consensus, Sanofi slightly exceeded its 2024 guidance. The 2025 outlook was encouraging. Moreover, the investors welcomed the management’s ..."
Pages
65
Language
English
Published on
30/01/25
You may also be interested by these reports :
30/06/26
The recent US Supreme Court decision in the Roundup litigations, went in favour of Bayer, and brings the firm very close to ending this chapter. Even ...
24/06/26
Rather than trying to figure out who will win the obesity race, why not bet on more defensive upstream API production?
23/06/26
Our estimates for 2026 and 2027 are significantly affected by net financial expenses. The firm raised $5.5bn to fund the Merus acquisition, which is ...
19/06/26
Evaluating Pharma’s Defences